Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves
May 05 2021 - 9:47AM
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), whose primary
mandate is to focus on international procurement, logistics, and
delivery of Personal Protective Equipment (“
PPE)
and wellness products, is pleased to provide an update on the
performance of the exclusivity contract to supply medical
examination gloves for North America.
On March 11, 2021 (see Press Release), Relevium
announced the procurement and subsequent delivery of the first
production batch of Personal Protective Equipment
(“PPE”) from a Supply Agreement entered into
during the last quarter of 2020 with 24 Clean
Energy (the “Supplier”), a manufacturer and distributor of
high-end medical grade nitrile gloves. The Company also announced
it had obtained the “exclusive” North American rights to market the
“DI-Line” brand of medical grade gloves, a much needed and
sought-after PPE product.
The Thailand based supplier was to commence
delivery of the first containers in the month of April 2021. Due to
various issues relating to the COVID-19 pandemic, causing delays in
the entire international supply chain cycle, the supplier has
informed Relevium management to expect the first shipment to be
delivered starting in the month of May, with the final delivery to
its customers in the month of June.
The total number of units to be shipped to the
port of Los Angeles is approximately 300,000 boxes (the First
Phase) out of a total of 500,000 boxes (total order). The medical
examination gloves are to be delivered to healthcare institutions
in the United States, and form part of the initial launch of the
suppliers “brand” into the North American market.
Aurelio Useche, CEO of Relevium stated: “We will
continue to closely monitor the execution of this contract, and we
expect to deliver a high-value product to our valued customer base.
Our distribution partnership with H-Source Holdings provides the
Company with access to Hospital Groups across the United States in
a safe, highly efficient and complaint delivery platform, which we
will continue to leverage as we enroll new clients into our
program”.
About Relevium
TechnologiesRelevium Technologies Inc.,
is a publicly traded Company, focussed on international
procurement, logistics, and delivery of Personal Protective
Equipment (“PPE) into the North American
marketplace. Utilizing trusted vendors and suppliers, and
integrating a comprehensive, state-of-the-art supply chain,
Artificial Intelligence (“AI), and Blockchain technology, enables a
highly secure and compliant platform for delivery of PPE equipment
to Governments, Hospitals, Foundations, and various
Institutions. Biocannabix Health
Corporation, a wholly owned subsidiary of Relevium
Technologies Inc., is focused on Paediatric and Geriatric
applications of Cannabinoid nutraceutical and medical food
formulations. The principal business of the Company is the
identification, evaluation, acquisition and operation of brands and
businesses in the health and wellness markets and cannabinoids.
Neither the
TSX Venture
Exchange nor its
Regulation Services Provider
(as that term
is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that the Company will be able to apply
for and ultimately obtain an ACMPR licence, the proposed business
of Biocannabix will develop as anticipated, that the Company will
raise sufficient funds to develop the Biocannabix business, and
that the Company will obtain all requisite regulatory
approvals.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the risk that
the proposed business developments may not occur as planned; the
timing and receipt of requisite approvals and failure to raise
sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website: www.releviumtechnologies.com
Like us on FacebookFollow us on Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024